Cipla Ltd’s Acquisition Of CPink, CDense, Productiv and Folinin


Khaitan & Co represented Wanbury Limited in the deal.

Indian pharmaceutical major Cipla Ltd acquired four women-focused nutraceutical products from Mumbai-based drugmaker Wanbury Ltd.

The four brands – CPink, CDense, Productiv and Folinine -have a market size of Rs 3,100 crore in India with sales value of Rs 59.6 crore, said Cipla in a stock market disclosure.

Nikhil Chopra, head of India business at Cipla, said that the acquisition will help the company cater to a wide range of patient needs including nutritional deficiencies and bone and sexual health.

Wanbury, founded in 1990, is engaged in the sales and marketing of active pharmaceutical ingredients (APIs) in over 50 countries, according to its website. It is also involved in the formulation business.

The Khaitan team was led by partner Bhavik Narsana (Picture), Niharika Mepani (Principal Associate) and Pujitha Gullapalli (Associate), Vinita Krishnan (Director) and Jimmy Bhatt (Principal Associate), Dinesh Agrawal (Executive Director) and Mayank Jain (Principal Associate).

Involved fees earner: Dinesh Agrawal – Khaitan & Co.; Jimmy Bhatt – Khaitan & Co.; Pujitha Gullapalli – Khaitan & Co.; Mayank Jain – Khaitan & Co.; Vinita Krishnan – Khaitan & Co.; Niharika Mepani – Khaitan & Co.; Bhavik Narsana – Khaitan & Co.;

Law Firms: Khaitan & Co.;

Clients: Wanbury Limited;